Sanofi and Regeneron Expand Dupixent Alliance in $8 Billion Immunology Deal

Sanofi and Regeneron said Thursday they are expanding their two-decade immunology alliance in a deal worth up to $8 billion, adding four next-generation, long-acting antibodies to the partnership that produced Dupixent, the world's leading treatment for type 2 inflammation.

The headline is $8 billion. The commitment is $1 billion.

The headline number is $8 billion. The committed number is $1 billion. Under the expanded license and collaboration agreement announced Thursday, Sanofi will pay Regeneron $1 billion upfront, with up to $7 billion more in development, regulatory and commercial milestone payments if the new medicines clear specified development and sales gates. The two companies will equally share development and commercialization costs for the new programs and split future global profits 50/50. Regeneron will lead research and development; Sanofi will lead global commercial efforts. The existing Dupixent profit-sharing terms do not change.

This is a staged option on the next generation of a franchise, not an acquisition. The $8 billion is a ceiling; the cash committed today is the $1 billion upfront plus shared development spending. Future payments arrive only if programs clear specified gates - a structure that keeps both companies exposed to execution while giving Sanofi a financed pipeline beyond the Dupixent cycle.

The four antibodies

The agreement adds four Regeneron-invented, long-acting antibodies to the alliance. The most advanced is REGN20423, a long-acting interleukin-13 antibody now in a Phase 1 clinical trial for atopic dermatitis. The other three - a long-acting IL-4xIL-13 bispecific and two preclinical antibodies targeting IL-4 and interleukin-4 receptor alpha - are expected to enter clinical studies in 2027.

Regeneron also secured an option to pull Sanofi's lunsekimig, an investigational bispecific Nanobody therapy targeting TSLP and IL-13, into the collaboration once it completes Phase 3 trials for chronic obstructive pulmonary disease.

The Dupixent clock

The urgency is Dupixent. The alliance dates to 2003, and its flagship has become the world-leading treatment for diseases driven by type 2 inflammation: more than 1.5 million people take Dupixent across nine indications, from atopic dermatitis and asthma to nasal polyps and COPD, and regulators in more than 60 countries have approved it in one or more uses.

But the blockbuster is set to lose patent protection in 2031, and investors have been pressing Sanofi on what carries the franchise next. The four new programs all target the same type 2 inflammation pathways; longer dosing intervals and broader biological targeting are the wager for defending the franchise against the next wave of competitors.

An early win for the new CEO

Sanofi shares rose 2% in early trading Thursday, climbing as much as 3.6% before settling about 1% higher. The market read the deal as an early win for Belen Garijo, who took over as Sanofi's chief executive in May and is running a strategic review aimed at faster decision-making.

Jefferies analyst Michael Leuchten said the expansion "should be viewed positively, as it signals the new CEO's proactive focus on the most important yet addressable uncertainties investors face, as well as the speed of progress." Barclays noted that Garijo's predecessor, Paul Hudson, had tried and failed to expand the partnership. The agreement also settles prior collaboration-related litigation between the two companies, removing a legal overhang.

The 8 am call, and whether the optionality pays

Regeneron and Sanofi will host a conference call for investors and analysts at 8:00 am ET Thursday, with a presentation posted to both companies' investor-relations sites. The questions that matter: whether REGN20423's Phase 1 data justify the upfront check, whether the three preclinical programs actually reach the clinic in 2027, and whether Regeneron exercises its lunsekimig option after the COPD Phase 3 readout.

The $8 billion is a ceiling, not a check. Sanofi has bought time and optionality ahead of the patent cliff; execution decides whether it bought anything more.